ALKS 2680 Clinical Trials (2026): 7 Studies for Narcolepsy Type 1 & Narcolepsy Type 2

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

7 ALKS 2680 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Narcolepsy Type 1 & Narcolepsy Type 2) and 1,013 total planned enrollment. 3 Phase 3 ALKS 2680 trials and 3 Phase 2 are listed. 5 ALKS 2680 clinical trials are actively recruiting at 94 U.S. sites across 20 states. Most recent activity: NCT06767683 (Jun 2028).

Where to Participate: All ALKS 2680 Trial Sites in the U.S. (94 sites across 20 states)

Every actively recruiting ALKS 2680trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
ALAlkermes Investigator SiteCullman35055NCT06843590Map
AZAlkermes Investigator SitePhoenix85054NCT06767683Map
AZAlkermes Investigator SitePhoenix85054NCT06843590Map
ARAlkermes Investigational SiteLittle Rock72211NCT06767683Map
ARAlkermes Investigator SiteLittle Rock72211NCT06843590Map
CAAlkermes Investigational SiteLos Angeles90025NCT06767683Map
CAAlkermes Investigational SiteLos Angeles90025NCT07455383Map
CAAlkermes Investigator SiteLos Angeles90025NCT06843590Map
CAAlkermes Investigator SiteRedwood City94063NCT06843590Map
CAAlkermes Investigator SiteSan Francisco94158NCT06767683Map
CAAlkermes Investigator SiteSan Francisco94143NCT06843590Map
CAAlkermes Investigational SiteStanford94305NCT06767683Map
COAlkermes Investigational SiteBoulder80301NCT07455383Map
COAlkermes Investigational SiteBoulder80301NCT07502443Map
COAlkermes Investigational SiteColorado Springs80918NCT06767683Map
COAlkermes Investigator SiteColorado Springs80918NCT06843590Map
FLAlkermes Investigational SiteBrandon33511NCT06767683Map
FLAlkermes Investigational SiteBrandon33511NCT07455383Map
FLAlkermes Investigational SiteBrandon33511NCT07502443Map
FLAlkermes Investigator SiteBrandon33511NCT06843590Map
FLAlkermes Investigational SiteMaimi33176NCT07502443—
FLAlkermes Investigational SiteMiami33176NCT06767683Map
FLAlkermes Investigational SiteMiami33176NCT07455383Map
FLAlkermes Investigator SiteMiami33176NCT06843590Map
FLAlkermes Investigational SiteWinter Park32789NCT06767683Map
FLAlkermes Investigational SiteWinter Park32789NCT07455383Map
FLAlkermes Investigational SiteWinter Park32789NCT07502443Map
FLAlkermes Investigator SiteWinter Park32789NCT06843590Map
GAAlkermes Investigational SiteAtlanta30328NCT06767683Map
GAAlkermes Investigational SiteAtlanta30328NCT07540897Map
GAAlkermes Investigator SiteAtlanta30328NCT06843590Map
GAAlkermes Investigational SiteMacon31210NCT06767683Map
GAAlkermes Investigational SiteMacon31210NCT07455383Map
GAAlkermes Investigational SiteMacon31210NCT07502443Map
GAAlkermes Investigational SiteMacon31210NCT07540897Map
GAAlkermes Investigator SiteMacon31210NCT06843590Map
GAAlkermes Investigational SiteStockbridge30281NCT06767683Map
GAAlkermes Investigator SiteStockbridge30281NCT06843590Map
ILAlkermes Investigational SitePeoria61637NCT06767683Map
ILAlkermes Investigator SitePeoria61637NCT06843590Map
KSAlkermes Investigator SiteKansas City66160NCT06843590Map
MAAlkermes Investigational SiteNewton02459NCT07455383Map
MAAlkermes Investigational SiteNewton02459NCT07502443Map
MIAlkermes Investigational SiteLansing48911NCT06767683Map
MIAlkermes Investigational SiteLansing48911NCT07455383Map
MIAlkermes Investigator SiteLansing48911NCT06843590Map
MIAlkermes Investigational SiteSterling Heights48314NCT06767683Map
MOAlkermes Investigational SiteSt Louis63123NCT07455383Map
NEAlkermes Investigational SiteLincoln68506NCT06767683Map
NEAlkermes Investigator SiteLincoln68506NCT06843590Map
NJAlkermes Investigational SiteMiddletown07748NCT06767683Map
NJAlkermes Investigator SiteMiddletown07748NCT06843590Map
NCAlkermes Investigational SiteDenver28037NCT06767683Map
NCAlkermes Investigator SiteDenver28037NCT06843590Map
NCAlkermes Investigational SiteHuntersville28708NCT06767683Map
NCAlkermes Investigator SiteHuntersville28078NCT06843590Map
OHAlkermes Investigational SiteCanton44718NCT06767683Map
OHAlkermes Investigator SiteCanton44718NCT06843590Map
OHAlkermes Investigational SiteCincinnati45212NCT06767683Map
OHAlkermes Investigational SiteCincinnati45245NCT06767683Map
OHAlkermes Investigational SiteCincinnati45245NCT07455383Map
OHAlkermes Investigational SiteCincinnati45245NCT07502443Map
OHAlkermes Investigator SiteCincinnati45245NCT06843590Map
OHAlkermes Investigator SiteCleveland44195NCT06843590Map
OHAlkermes Investigational SiteDublin43017NCT06767683Map
PAAlkermes Investigational SiteAbington19001NCT06767683Map
PAAlkermes Investigator SiteDanville17822NCT06843590Map
PAAlkermes Investigator SitePhiladelphia19107NCT06843590Map
PAAlkermes Investigational SiteWyomissing19610NCT06767683Map
PAAlkermes Investigational SiteWyomissing19610NCT07455383Map
PAAlkermes Investigational SiteWyomissing19610NCT07502443Map
PAAlkermes Investigator SiteWyomissing19610NCT06843590Map
SCAlkermes Investigational SiteColumbia29201NCT06767683Map
SCAlkermes Investigational SiteColumbia29201NCT07455383Map
SCAlkermes Investigational SiteColumbia29201NCT07502443Map
SCAlkermes Investigator SiteColumbia29201NCT06843590Map
TXAlkermes Investigational SiteAustin78731NCT06767683Map
TXAlkermes Investigational SiteAustin78731NCT07455383Map
TXAlkermes Investigational SiteAustin78731NCT07502443Map
TXAlkermes Investigator SiteAustin78731NCT06843590Map
TXAlkermes Investigational SiteDallas75251NCT07540897Map
TXAlkermes Investigational SiteSan Antonio78229NCT06767683Map
TXAlkermes Investigational SiteSan Antonio78229NCT07455383Map
TXAlkermes Investigational SiteSan Antonio78229NCT07502443Map
TXAlkermes Investigational SiteSan Antonio78229NCT07540897Map
TXAlkermes Investigator SiteSan Antonio78229NCT06843590Map
TXAlkermes Investigational SiteSugar Land77478NCT06767683Map
TXAlkermes Investigational SiteSugar Land77478NCT07455383Map
TXAlkermes Investigational SiteSugar Land77478NCT07502443Map
TXAlkermes Investigational SiteSugar Land77478NCT07540897Map
TXAlkermes Investigator SiteSugar Land77478NCT06843590Map
TXAlkermes Investigator SiteSugarland77478NCT06843590—
WIAlkermes Investigational SiteMadison53706NCT06767683Map
WIAlkermes Investigator SiteMadison53792NCT06843590Map

ALKS 2680 clinical trials at a glance: phase × recruitment status

PhaserecruitingcompletedTotal
P2123
P2/P311
P333

Recruiting ALKS 2680 clinical trials (5)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT06767683A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaP2/P3Narcolepsy Type 1256Jan 2025
NCT07540897A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)P3Narcolepsy Type 1150Jun 2026
NCT07502443Brilliance NT2A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2P3Narcolepsy Type 2176Apr 2026
NCT07455383Brilliance NT1A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1P3Narcolepsy Type 1150Apr 2026
NCT06843590Vibrance-3A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaP2Idiopathic Hypersomnia96May 2025

ALKS 2680 clinical trials by indication

Narcolepsy Type 1 (4)

NCTAcronymPhaseStatusTitle
NCT06767683—P2/P3recruitingA Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT07540897—P3recruitingA Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
NCT07455383Brilliance NT1P3recruitingA Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
NCT06358950Vibrance-1P2completedA Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)

Narcolepsy Type 2 (2)

NCTAcronymPhaseStatusTitle
NCT07502443Brilliance NT2P3recruitingA Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
NCT06555783Vibrance-2P2completedA Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2

Idiopathic Hypersomnia (1)

NCTAcronymPhaseStatusTitle
NCT06843590Vibrance-3P2recruitingA Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

ALKS 2680 pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
Brilliance NT2NCT07502443P3recruitingNarcolepsy Type 2176—
Brilliance NT1NCT07455383P3recruitingNarcolepsy Type 1150—
Vibrance-3NCT06843590P2recruitingIdiopathic Hypersomnia96—
Vibrance-2NCT06555783P2completedNarcolepsy Type 293—
Vibrance-1NCT06358950P2completedNarcolepsy Type 192—

All ALKS 2680 trials (7)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT06767683A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaP2/P3recruiting256Alkermes, Inc.Jan 2025
NCT07540897A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)P3recruiting150Alkermes, Inc.Jun 2026
NCT07502443Brilliance NT2A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2P3recruiting176Alkermes, Inc.Apr 2026
NCT07455383Brilliance NT1A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1P3recruiting150Alkermes, Inc.Apr 2026
NCT06843590Vibrance-3A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaP2recruiting96Alkermes, Inc.May 2025
NCT06555783Vibrance-2A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2P2completed93Alkermes, Inc.Jul 2024
NCT06358950Vibrance-1A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)P2completed92Alkermes, Inc.Mar 2024

ALKS 2680 clinical trials: frequently asked questions

How many ALKS 2680 clinical trials are there?
7 ALKS 2680 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 2 are marked completed.
Are ALKS 2680 clinical trials recruiting in 2026?
Yes — 5 ALKS 2680 trials are actively recruiting in 2026, with 94 U.S. sites across 20 states. See the recruiting trials and the per-state site list further down this page.
What conditions is ALKS 2680 being studied for?
ALKS 2680 is being studied for Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia. The trials are grouped by indication on this page.
What phase is ALKS 2680 in?
ALKS 2680 clinical trials span 3 Phase 3, 3 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors ALKS 2680 clinical trials?
The lead sponsor across the most ALKS 2680 trials is Alkermes, Inc.. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming ALKS 2680as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai:

ALKS 2680 overview